Eli Lilly halves $2.5 billion Alzey bet

Eli Lilly will build only the "minimum scope" of its $2.5 billion plant in Alzey, Germany. The shell is almost finished and 300 workers have already been hired, but the promised expansion to 1,000 jobs is gone.

Within hours, Boehringer Ingelheim cancelled €900 million in German investment planned for 2027 to 2030. Both companies blamed the same measure: Berlin's new law to cut health-insurance spending.

Berlin's fiscal corner

The law, formally the GKV-Beitragssatzstabilisierungsgesetz, is Germany's health insurance contribution stabilisation act. It comes from a real fiscal problem. Germany's average health insurance contribution reached a record 17.5% of gross wages in 2026, and the country's council of economic advisers says total social contributions could hit 49.7% by 2040 without reform.

Berlin wants €16.3 billion in health-system savings by 2027. For pharmaceutical companies, the key mechanism is a "dynamic manufacturer rebate": a compulsory discount on drug prices that rises automatically when insurance spending grows.

The dispute is over how far that rebate can climb. The vfa, Germany's main pharma lobby, puts it at around 20% of list prices by 2030. Pharma Deutschland, which represents generic and mid-sized drugmakers, warns it could reach 50%.

That automatic escalation is what companies say breaks the investment case. Today's rebate level is one problem; the bigger one is that the future discount is written into the system before a company knows what it will be producing, at what scale, and at what price. Pharma accounts for about 3.3% of German health-insurance spending but is expected to carry roughly 12% of the planned savings.

Paris has the chequebook ready

Boehringer's move towards France did not happen in isolation. On 1 June, the company pledged €500 million across four French production sites at Emmanuel Macron's "Choose France" investment summit. Two days later came the €900 million German cancellation.

The total pharma investment announced at Choose France reached €600 million, three times the previous year's figure. France is not simply offering nicer speeches. It is using political certainty, public attention and investment signalling to pull projects across the border.

EY's attractiveness barometer shows foreign investment projects in Germany have fallen 44% since 2019, compared with a 28% decline in France. Boehringer's Germany chief put the message plainly: "The next innovation will, as things stand, not go to Germany".

84% margins against mandatory rebates

Eli Lilly reported revenue of $65.2 billion in 2025, up 45% in one year. Its gross margin was 84.3%, meaning 84 cents of every dollar in revenue remained after production costs.

Boehringer reported €27.8 billion in revenue, up 7.3%. German prices for patented drugs are already 114% of the European average. On those numbers, the claim that higher German rebates are commercially unbearable needs to be read as a bargaining position, not as a balance-sheet fact.

The episode also shows where Brussels runs out of road. In May 2026, the EU reached a provisional deal on its Critical Medicines Act, meant to bring pharmaceutical production back to Europe. For Malta, as for other small member states, that is not an abstract industrial slogan: medicine supply depends on decisions taken in bigger markets, often long before smaller countries can react.

But healthcare pricing remains a national competence under the EU treaties. Each government sets its own drug prices, and Brussels cannot override that. The EU can encourage factories to be built in Europe. It cannot force Germany to make those factories financially attractive.

Europe's share of global API production has fallen from 63% in 1981 to roughly 6% today. An API is the active pharmaceutical ingredient, the chemical compound that makes a medicine work. The Critical Medicines Act's proposed €5 billion fund is still a line in a future EU budget, not money already committed.

Berlin is stuck between two pressures. It has to control health costs that are squeezing workers and employers through record contributions. But if investment goes to Toulouse and Cork instead of Alzey and Ingelheim, Europe's pharmaceutical sovereignty is weakened from within: not by Beijing, but by the fiscal emergencies of its own member states.